WT-161

Manufacturer	MedChem Express
Category	Oncology Neuroscience Aging & Neurological Disorders Neural Epigenetics Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer Lymphatic System Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Amount	25 mg
Item no.	HY-100871-25mg
Targets	HDAC; Apoptosis
CASRN	1206731-57-8
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM[1]. WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2)[2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	458.55
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : ≥ 100 mg/mL
Manufacturers Target	Apoptosis; Beta-lactamase; HDAC
Isoform	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8
Pathway	Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100871-25mg-safety-datasheet.pdf